BioSpace

00:24:32

Lilly wheels and deals, Moderna gets boost on...

BioSpace ·

2026/05/27

Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines, Lilly scooped up preclinical biotech Engage Bio for $202 million and teamed up with AI company Collaborative Drug Discovery for its life sciences data management solutions.These deals and Lilly’s skyrocketing revenue pushed the Indianapolis-based company to the top of IDEA Pharma’s

en

00:23:17

Inside Germany’s biotech capital infrastructure and...

BioSpace ·

2026/05/21

In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Andera Life Sciences. They examine Germany’s biotech and life sciences landscape, focusing on the scientific, infrastructure and policy shifts required to enable European companies to scale globally while remaining anchored in Europe.Host⁠Jennifer C. Smith-Parker, Director of Insights,

en

00:26:48

FDA’s absent leaders, the millions pharma CEOs make,...

BioSpace ·

2026/05/20

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary’s tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would

en

00:20:25

From MSCs to iPSCs: building the cell therapy future

BioSpace ·

2026/05/14

In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells, exploring the science behind them, the manufacturing challenges, and the potential for scalable, engineered next-generation therapies.HostJennifer C. Smith-Parker, Director of Insights,

en

00:15:42

Makary’s out at FDA, Sanofi’s priority voucher...

BioSpace ·

2026/05/13

Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ouster. The president initially denied this account, originally from The Wall Street Journal, on Saturday morning, but appears to have now confirmed the plan. This confusion underscores a key theme in Robert F. Kennedy Jr.’s health department: lack of transparency and clear communication. Makary’s exit also

en

00:18:00

Fibrosis, IPF and the search for better therapies

BioSpace ·

2026/05/07

In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsGeorg Vo Beiske, CEO, Tribune TherapeuticsJonas Hallén, Co-Founder & CMO, Calluna PharmaDisclaimer: The views expressed in

en

00:22:30

Pfizer, Lilly, more report Q1, FDA names acting CBER...

BioSpace ·

2026/05/06

First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the New York pharma. Analysts were more than satisfied with Lilly’s 56% revenue increase, though the company itself appeared to want more—a feat executives believe it could have achieved had it not lowered prices on many of its medicines. Meanwhile, a host of small– to-medium biotechs are

en

00:26:22

Pfizer, Lilly, more report Q1, FDA names acting CBER...

BioSpace ·

2026/05/06

First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the New York pharma. Analysts were more than satisfied with Lilly’s 56% revenue increase, though the company itself appeared to want more—a feat executives believe it could have achieved had it not lowered prices on many of its medicines. Meanwhile, a host of small– to-medium biotechs are

en

00:21:40

What makes life science angel investment work?

BioSpace ·

2026/04/30

In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bio Angels and partner at Alloy Bio Consulting. We discuss why a life sciences-only angel group matters, how they evaluate opportunities, and the importance of strong teams, capital efficiency and a realistic path to exit.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsYaniv Sneor, Founder, Mid Atlantic Bio AngelsAlex Pederson,

en

00:22:14

Q1 earnings take off, Lilly strikes deals, Regeneron...

BioSpace ·

2026/04/29

First quarter earnings are coming in at a rapid pace, with Sanofi and Novartis defending patents for Dupixent and Lutathera, respectively, and Sanofi welcoming Belén Garijo as CEO. Still to come this week are Eli Lilly, AstraZeneca, Regeneron and many more.Lilly will undoubtedly discuss its recent streak of dealmaking, including a $2.25 billion pact with AI biotech Profluent, plus buyouts of Ajax Therapeutics for up to $2.3 billion and Kelonia Therapeutics for up to $7 billion.Meanwhile, Regeneron

en

00:21:42

The next era of diabetes management

BioSpace ·

2026/04/23

In this episode of Denatured, you'll be hearing from Dr. Sarah Howell, CEO at Arecor Therapeutics and Dr. Wendy S. Lane, clinical endocrinologist and diabetologist. We examine how increasingly connected and tailored diabetes technologies are reframing the field’s central opportunity around minimizing the day-to-day demands of managing the condition.

en

00:26:08

Trump’s psychedelics push, Lilly’s up to $7B CAR T...

BioSpace ·

2026/04/22

After entering the CAR T arena in February, Eli Lilly jumped onto the in vivo bandwagon, penning a deal worth up to $7 billion for Kelonia Therapeutics and its gene therapy delivery tech iGPS. Meanwhile, Belgium-based UCB scooped up Neurona Therapeutics for $650 million upfront and up to $500 million in milestone payments.On the policy front, President Donald Trump signed a new executive order that analysts believe could help psychedelic therapies become the “key next wave” of mental health

en

00:20:10

Funding the Future of European Biotech

BioSpace ·

2026/04/16

In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsEdoardo Negroni, Co-Founder & Managing Partner, AurorA-TTNaveed Siddiqi, Senior Partner,

en

00:17:53

J&J targets $100B revenue, Replimune rebuffed again...

BioSpace ·

2026/04/15

Johnson & Johnson kicked off Q1 earnings season with a “modest” beat, raking in $24.1 billion in sales as it targets $100 billion in revenue in 2026. J&J, as always, is the first to report results from a first quarter that has seen a wave of deals across biopharma; this M&A rush is expected to headline investor calls as more companies, including Novo Nordisk and Eli Lilly, report their Q1 results in the coming days. Meanwhile, IPOs are also on an upswing, with Kailera Therapeutics eyeing

en

00:08:33

Bonus: Q1 2026 Job Market Update

BioSpace ·

2026/04/14

Listen to BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss 2026 job market performance so far, sharing the latest BioSpace data.They touch on positive signs they saw between January and March, including a reduced number of layoffs, and what this year might have in store for those seeking employment in 2026.

en

00:17:15

Automation, Collaboration and the Future of Advanced...

BioSpace ·

2026/04/09

In this episode of Denatured, you'll listen to Jason Jones, head of global business development at Cellular Origins and Alexander Seyf, founder & CEO of Autolomous. They discuss how cell and gene therapy manufacturing is facing growing pressure to scale more quickly and efficiently, driving developers and manufacturers toward automation, digitization, robotics and broader collaboration across the ecosystem.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJason Jones, Head of

en

00:25:21

Lilly’s Foundayo Nod Launches New Battle With Novo,...

BioSpace ·

2026/04/08

Eli Lilly won FDA approval last week for orforglipron—now Foundayo— officially launching what promises to be a heated battle between Lilly and chief rival Novo Nordisk. Elsewhere, the M&A space keeps chugging along, with Gilead Sciences gobbling up partner Tubulis for up to $5 billion and Neurocrine Biosciences nabbing Soleno Therapeutics for $2.9 billion. The industry will be on high alert for more deals, as analysts say Amgen, AbbVie and Bristol Myers Squibb all have more money to spend. At

en

00:18:30

The Radiotherapeutics Moment: How Isotopes are...

BioSpace ·

2026/04/02

In this episode of Denatured, you'll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech's next big frontier.Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Marc Hedrick, President & CEO, Plus Therapeutics Philip Kantoff, Co-founder & CEO, Convergent

en

00:23:27

Biopharma M&A Heats Up, Rare Diseases Win Three...

BioSpace ·

2026/04/01

Biogen, Eli Lilly and Merck spent more than $20 billion in the past week to swallow biotechs with approved products or promising drug candidates—representing three of this year’s four biggest takeovers. First, Merck picked up Terns Pharmaceuticals and its mid-stage leukemia drug for $6.7 billion. Then, on Tuesday, Lilly and Biogen struck, acquiring Centessa Pharmaceuticals and Apellis Pharmaceuticals respectively.Those big-ticket deals aren’t the only recent transactions, however. Others include

en

00:22:56

Beyond Buzzwords in Longevity Investing

BioSpace ·

2026/03/26

In this episode, you'll be listening to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We discuss how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions. HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsSergey Jakimov, Managing Partner, LongeVCArtem Trotsyuk, Operating Partner-US, LongeVC

en

All Episodes

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Show Me the Science with Luke O"Neill

Newstalk

Planetterrian Daily

Patrick · Nerra Network

Sleep Science

Sleep Science

BioSpace

BioSpace